Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer

Mirat Shah

Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

Mallorie H. Fiero

Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

Joyce Cheng

Ting-Yu Chen

Gwynn Ison

Mirat Shah, MD, Mallorie H. Fiero, PhD, Joyce Cheng, PhD, Ting-Yu Chen, PhD, and Gwynn Ison, MD, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD; Richard Pazdur, MD, and Laleh Amiri-Kordestani, MD, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD, Oncology Center of Excellence (OCE), US Food and Drug Administration, Silver Spring, MD

Richard Pazdur

From the Oncology Center of Excellence (G.U.M., R.P.) and the Office of the Commissioner (N.N.B., R.M.C.), Food and Drug Administration, Silver Spring, MD.

Laleh Amiri-Kordestani